|
gptkbp:instanceOf
|
gptkb:chemical_compound
histone deacetylase inhibitor
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XX50
|
|
gptkbp:CASNumber
|
149647-78-9
|
|
gptkbp:discoveredBy
|
gptkb:Paul_Marks
|
|
gptkbp:hasMolecularFormula
|
C14H20N2O3
|
|
gptkbp:hasSMILES
|
CCCCCC(=O)N(H)NC1=CC=CC=C1O
|
|
gptkbp:hasUNII
|
UXL6BB7R8E
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SAHA
|
|
gptkbp:IUPACName
|
gptkb:N-hydroxy-N'-phenyloctanediamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Merck_&_Co.
|
|
gptkbp:mechanismOfAction
|
inhibits histone deacetylases, leading to accumulation of acetylated histones and proteins
|
|
gptkbp:molecularWeight
|
264.32 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:DB02546
5311
CHEMBL1173
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
diarrhea
anorexia
fatigue
thrombocytopenia
dysgeusia
increased creatinine
|
|
gptkbp:synonym
|
gptkb:Vorinostat
|
|
gptkbp:target
|
histone deacetylase
|
|
gptkbp:usedFor
|
treatment of cutaneous T-cell lymphoma
|
|
gptkbp:bfsParent
|
gptkb:vorinostat
|
|
gptkbp:bfsLayer
|
6
|